Hanmi announces start on Phase 3 clinical trials for ‘efpeglenatide’ in 2017

Published: 2016-11-01 11:01:16

Updated: 2016-11-01 11:01:16

On the 28^th, Hanmi Pharm(CEO Kwan-Soon Lee) announced it plans to start Phase 3 clinical trials of a new antidiabetic, whose license was agreed with Sanofi last year, ‘efpeglenatide,’ in 2017.

Hanmi Pharm and Sanofi was originally planning to have the Phase 3 clinical trials in the 4^th quarter of 2016, but changed the plan as the manufacturing process of the drug was delayed.

Sanofi is expe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.